Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...
The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...
Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...
Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...
There are rumours that a pharma 'mega-merger' – between AstraZeneca and Bristol Myers Squibb – is in the offing, ending several years without this type of deal. A report in the Financial Times ...
According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...
August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...
The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...
Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...
City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...
From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...
US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results